Immuneering (IMRX) Stock Price, Quote, News & History | Benzinga

Immuneering Corp (IMRX) Stock Price, Quote, News & History

IMRXNASDAQ

Trade with Public

Trade with Public

$5.06

-0.14-2.69%

At close: Aug 14, 5:00 PM EST

$5.16

0.101.98%

After Hours: 6:19 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$5.18

Close

$5.06

Volume / Avg.

524.22K / 1.50M

Day Range

$4.93 - $5.18

52 Wk Range

2.90 - 10.08

Market Cap

$333.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

31.37%

Days to Cover

20.37

Recent Immuneering Corporation News

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.

Avi Kapoor

Crude Oil Edges Higher; US Consumer Sentiment Falls In May

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low. Oil up, gold and silver down. European and Asian markets closed higher.

Avi Kapoor

Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday

Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.

Avi Kapoor

Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga Senior Editor

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-56.75M

Investing Cash Flow (TTM)

-141.32M

Financing Cash Flow (TTM)

213.04M

Free Cash Flow (TTM)

-56.99M

Capital Expenditure (TTM)

-238.46K

Net Change in Cash (TTM)

14.97M

Analyst Trends and Forecast

1

Mar

1

May

2

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$181.10M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.77

Earnings Yield % (TTM)

-17.85%

Earnings Yield % (FWD)

-20.44%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.95

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$41.32M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$5.18

Close

$5.06

Volume / Avg.

524.22K / 1.50M

Day Range

$4.93 - $5.18

52 Wk Range

2.90 - 10.08

Market Cap

$333.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

31.37%

Days to Cover

20.37

About

Sector

Health Care

Industry

Biotechnology

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug dev...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Immuneering (IMRX) stock?

A

You can purchase shares of Immuneering (NASDAQ:IMRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Immuneering (IMRX) competitors?

A

Other companies in Immuneering’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Immuneering (IMRX) stock?

A

Immuneering has a consensus price target of $15.13.

Q

What is the current price for Immuneering (IMRX)?

A

The stock price for Immuneering (NASDAQ: IMRX) is $5.16 last updated August 14, 2026 at 6:19 PM EDT.

Q

Does Immuneering (IMRX) pay a dividend?

A

There are no upcoming dividends for Immuneering.

Q

When is Immuneering (NASDAQ:IMRX) reporting earnings?

A

Immuneering does not have any upcoming earnings scheduled.

Q

Is Immuneering (IMRX) going to split?

A

There is no upcoming split for Immuneering.

Q

What sector and industry does Immuneering (IMRX) operate in?

A

Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.